Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
Jesse Hall,1 Michael Gillen,2 Sha Liu,1 Jeffrey N Miner,1 Shakti Valdez,1 Zancong Shen,1 Caroline Lee1 1Ardea Biosciences, Inc., San Diego, CA, USA; 2AstraZeneca, Gaithersburg, MD, USA Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatme...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-06-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/ppharmacokinetics-pharmacodynamics-and-tolerability-of-verinurad--peer-reviewed-article-DDDT |
id |
doaj-55ca08c1e27144f8af76c39e0986638d |
---|---|
record_format |
Article |
spelling |
doaj-55ca08c1e27144f8af76c39e0986638d2020-11-25T00:48:54ZengDove Medical PressDrug Design, Development and Therapy1177-88812018-06-01Volume 121799180738939Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjectsHall JGillen MLiu SMiner JNValdez SShen ZLee CJesse Hall,1 Michael Gillen,2 Sha Liu,1 Jeffrey N Miner,1 Shakti Valdez,1 Zancong Shen,1 Caroline Lee1 1Ardea Biosciences, Inc., San Diego, CA, USA; 2AstraZeneca, Gaithersburg, MD, USA Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of gout and asymptomatic hyperuricemia. This study evaluated verinurad pharmacokinetics, pharmacodynamics, and tolerability in healthy Japanese and non-Asian adult male subjects.Methods: This was a Phase I, randomized, single-blind, placebo-controlled study. Panels of 8 Japanese subjects were randomized to receive oral verinurad (2.5–15 mg) or placebo administered as a single dose in a fasted and fed state and as once-daily doses for 7 days in a fed state. Eight non-Asian subjects received verinurad 10 mg as a single dose (fasted and fed) and multiple doses in the fed state. Serial plasma/serum and urine samples were assayed for verinurad and uric acid. Safety was assessed by adverse events and laboratory data.Results: Of 48 randomized subjects, 46 (Japanese, 39; non-Asian, 7) completed the study. Following single or multiple doses in Japanese subjects, maximum plasma concentration (Cmax) and area under the plasma concentration–time curve (AUC) increased in a near dose-proportional manner. Time to Cmax (Tmax) was ~1.25–2.0 hours with fasting. A moderate-fat meal delayed Tmax (range 3.0–5.0 hours) and had a variable effect on AUC (0%–97% increase) and Cmax (0%–26% increase) across the dose groups. Following multiple verinurad 10 mg doses, Cmax and AUC were 38% and 23% higher, respectively, in Japanese vs non-Asian subjects, largely due to body weight differences. Mean reduction of serum urate following multiple verinurad 10 mg doses was 46% and 44% after 24 hours in Japanese and non-Asian subjects, respectively. Verinurad was well tolerated at all doses.Conclusion: Verinurad monotherapy lowered serum urate and was well tolerated in both healthy Japanese and non-Asian males, while small differences in plasma pharmacokinetics were observed. These data support further evaluation of once-daily verinurad as a treatment for gout and asymptomatic hyperuricemia. Keywords: pharmacokinetics, pharmacodynamics, selective uric acid reabsorption inhibitor, serum urate, urinary uric acidhttps://www.dovepress.com/ppharmacokinetics-pharmacodynamics-and-tolerability-of-verinurad--peer-reviewed-article-DDDTPharmacokineticspharmacodynamicsselective uric acid reabsorption inhibitorserum urateurinary uric acid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hall J Gillen M Liu S Miner JN Valdez S Shen Z Lee C |
spellingShingle |
Hall J Gillen M Liu S Miner JN Valdez S Shen Z Lee C Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects Drug Design, Development and Therapy Pharmacokinetics pharmacodynamics selective uric acid reabsorption inhibitor serum urate urinary uric acid |
author_facet |
Hall J Gillen M Liu S Miner JN Valdez S Shen Z Lee C |
author_sort |
Hall J |
title |
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects |
title_short |
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects |
title_full |
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects |
title_fullStr |
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects |
title_full_unstemmed |
Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects |
title_sort |
pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy japanese and non-asian male subjects |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2018-06-01 |
description |
Jesse Hall,1 Michael Gillen,2 Sha Liu,1 Jeffrey N Miner,1 Shakti Valdez,1 Zancong Shen,1 Caroline Lee1 1Ardea Biosciences, Inc., San Diego, CA, USA; 2AstraZeneca, Gaithersburg, MD, USA Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for treatment of gout and asymptomatic hyperuricemia. This study evaluated verinurad pharmacokinetics, pharmacodynamics, and tolerability in healthy Japanese and non-Asian adult male subjects.Methods: This was a Phase I, randomized, single-blind, placebo-controlled study. Panels of 8 Japanese subjects were randomized to receive oral verinurad (2.5–15 mg) or placebo administered as a single dose in a fasted and fed state and as once-daily doses for 7 days in a fed state. Eight non-Asian subjects received verinurad 10 mg as a single dose (fasted and fed) and multiple doses in the fed state. Serial plasma/serum and urine samples were assayed for verinurad and uric acid. Safety was assessed by adverse events and laboratory data.Results: Of 48 randomized subjects, 46 (Japanese, 39; non-Asian, 7) completed the study. Following single or multiple doses in Japanese subjects, maximum plasma concentration (Cmax) and area under the plasma concentration–time curve (AUC) increased in a near dose-proportional manner. Time to Cmax (Tmax) was ~1.25–2.0 hours with fasting. A moderate-fat meal delayed Tmax (range 3.0–5.0 hours) and had a variable effect on AUC (0%–97% increase) and Cmax (0%–26% increase) across the dose groups. Following multiple verinurad 10 mg doses, Cmax and AUC were 38% and 23% higher, respectively, in Japanese vs non-Asian subjects, largely due to body weight differences. Mean reduction of serum urate following multiple verinurad 10 mg doses was 46% and 44% after 24 hours in Japanese and non-Asian subjects, respectively. Verinurad was well tolerated at all doses.Conclusion: Verinurad monotherapy lowered serum urate and was well tolerated in both healthy Japanese and non-Asian males, while small differences in plasma pharmacokinetics were observed. These data support further evaluation of once-daily verinurad as a treatment for gout and asymptomatic hyperuricemia. Keywords: pharmacokinetics, pharmacodynamics, selective uric acid reabsorption inhibitor, serum urate, urinary uric acid |
topic |
Pharmacokinetics pharmacodynamics selective uric acid reabsorption inhibitor serum urate urinary uric acid |
url |
https://www.dovepress.com/ppharmacokinetics-pharmacodynamics-and-tolerability-of-verinurad--peer-reviewed-article-DDDT |
work_keys_str_mv |
AT hallj pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects AT gillenm pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects AT lius pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects AT minerjn pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects AT valdezs pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects AT shenz pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects AT leec pharmacokineticspharmacodynamicsandtolerabilityofverinuradaselectiveuricacidreabsorptioninhibitorinhealthyjapaneseandnonasianmalesubjects |
_version_ |
1725254314550624256 |